Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 (mut) measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiong, Ing S., Dillon, Richard, Ivey, Adam, Teh, Tse‐Chieh, Nguyen, Phillip, Cummings, Nicholas, Taussig, David C., Latif, Annie‐Louise, Potter, Nicola E., Runglall, Manohursingh, Russell, Nigel H., Raj, Kavita, Schwarer, Anthony P., Fong, Chun Yew, Grigg, Andrew P., Wei, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048658/
https://www.ncbi.nlm.nih.gov/pubmed/32458446
http://dx.doi.org/10.1111/bjh.16722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048658/
https://www.ncbi.nlm.nih.gov/pubmed/32458446
http://dx.doi.org/10.1111/bjh.16722

Ejemplares similares